标题
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 12, Issue 9, Pages 5895-5907
出版商
MDPI AG
发表日期
2011-09-16
DOI
10.3390/ijms12095895
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
- (2017) U. Pelzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
- (2015) Hayato Fujita et al. NEOPLASIA
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression
- (2011) M Seux et al. ONCOGENE
- Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma
- (2010) Weibin Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CD10+ Pancreatic Stellate Cells Enhance the Progression of Pancreatic Cancer
- (2010) Naoki Ikenaga et al. GASTROENTEROLOGY
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer
- (2010) Xin Hong et al. JOURNAL OF SURGICAL ONCOLOGY
- A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- (2010) E. M. O'Reilly et al. ONCOLOGIST
- Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
- (2009) J P Neoptolemos et al. BRITISH JOURNAL OF CANCER
- Dkk-3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas
- (2009) Dominic Fong et al. CANCER SCIENCE
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
- (2009) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer
- (2009) Yu-Ting Chang et al. PANCREAS
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
- Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins
- (2008) J. D. Young et al. XENOBIOTICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More